Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

• Published in: PLoS medicine Vol. 18; no. 3; p. e1003534
• Main Authors: Kim, Jane J, Simms, Kate T, Killen, James, Smith, Megan A, Burger, Emily A, Sy, Stephen, Regan, Catherine, Canfell, Karen
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 11.03.2021; Public Library of Science (PLoS)
• Subjects: Adults; Age; Analysis; Biology and Life Sciences; Calibration; Cervical cancer; Cervix; Complications and side effects; Cost analysis; Decision making; Disease; Disease transmission; Females; Genotypes; Health aspects; Human papillomavirus; Immunotherapy; Infections; Medical care, Cost of; Medical screening; Medicine and Health Sciences; Mortality; Multiple births; Natural history; Papillomavirus infections; Penis; Population; Prevention; Risk factors; Social Sciences; Surveillance; Teenagers; Vaccines; Vagina; Warts; Womens health; Young adults; United States; United States > US
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/JOURNAL.PMED.1003534

A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was evaluated to inform national guidelines. We utilized 2 independent HPV microsimulation models to evaluate the cost-effectiveness of extending the upper age limit of HPV vaccination in women (from age 26 years) and men (from age 21 years) up to age 30, 35, 40, or 45 years. The models were empirically calibrated to reflect the burden of HPV and related cancers in the US population and used standardized inputs regarding historical and future vaccination uptake, vaccine efficacy, cervical cancer screening, and costs. Disease outcomes included cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, as well as genital warts. Both models projected higher costs and greater health benefits as the upper age limit of HPV vaccination increased. Strategies of vaccinating females and males up to ages 30, 35, and 40 years were found to be less cost-effective than vaccinating up to age 45 years, which had an incremental cost-effectiveness ratio (ICER) greater than a commonly accepted upper threshold of $200,000 per quality-adjusted life year (QALY) gained. When including all HPV-related outcomes, the ICER for vaccinating up to age 45 years ranged from $315,700 to $440,600 per QALY gained. Assumptions regarding cervical screening compliance, vaccine costs, and the natural history of noncervical HPV-related cancers had major impacts on the cost-effectiveness of the vaccination strategies. Key limitations of the study were related to uncertainties in the data used to inform the models, including the timing of vaccine impact on noncervical cancers and vaccine efficacy at older ages. Our results from 2 independent models suggest that HPV vaccination for adult women and men aged 30 to 45 years is unlikely to represent good value for money in the US.